Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review

Women Warned Over Cancer Symptoms You Might See In Your Face That Most People Ignore

Experts have warned that women are 'more likely' to ignore this lesser-known cancer symptom.

While it would be impossible to be aware of every possible symptom of cancer, it is beneficial to know about a few of the lesser-known ones to look out for.

After all, being informed and proactive about symptoms could save someone's life.

And while it can present itself in all sorts of different ways, there is one symptom in particular that experts have warned women are 'more likely' to ignore.

Early detection of cancer can increase chances of treatment being a success, so it's important for people to know the signs.

Health experts are warning that lung cancer can cause symptoms on the face.

Experts are warning of the less-known symptoms of lung cancer. (Getty stock images)

This is because small cell lung tumours can block blood vessels in the chest, which prevents blood flow to the face.

It's seen to be a 'common symptom' of lung carcinoma, which definitely shouldn't be ignored.

The Reynolds Cancer Support House website said: "Some patients with lung cancer report noticing puffiness, swelling, or redness in the face."

When the cells are affected by cancer, red facial flushing, diarrhoea and wheezing are all common.

But there is also research on the psychological effects that this symptom can cause.

It's important not to ignore symptoms out of fear, as screening tests can detect malignancies in their earliest stages. But lung cancer isn't the only form of the disease that health professionals are warning about.

Women are 'more likely' to ignore this symptom. (Getty stock images)

Bowel cancer, also known as colorectal cancer, can be found anywhere in the large bowel, including the colon and the rectum. If left untreated, the disease can develop, eventually infecting lymph nodes and other organs.

And a new study has revealed that one ingredient could be connected to a rising number of colon cancer cases in Gen Z.

Certain kinds of cooking oils are the ingredient currently being looked at - as some experts warn of their connection to increased cancer risk.

Dr Karen Zaghiyan uses TikTok to promote accurate health advice, and has also issued a warning about the increase in cases of bowel cancers in young people.

The expert said in a video posted earlier this month: "We're seeing an alarming rise in young onset colorectal cancer.

"While nobody totally knows why exactly we're seeing this, a lot of people are suggesting - and the research shows - that perhaps it may be related to what we're eating."

AstraZeneca's Imfinzi Shows Positive Results In Phase 3 Trial For Treatment Of Limited-stage Small Cell Lung Cancer

1. Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In both the placebo group and treatment group, adverse events occurred in 24% of patients.

The Latest

The ADRIATIC trial, a multicenter, randomized, double-blind phase 3 study, investigated the effects of AstraZeneca's PD-L1 inhibitor Imfinzi (durvalumab) in patients with limited-stage small cell lung cancer and prior chemotherapy treatment. Results from the ADRIATIC trial demonstrate that Imfinzi met its primary outcomes of prolonging progression-free survival and overall survival compared to placebo-controlled patients. 46% of patients receiving Imfinzi had no disease progression after two years, compared to only 34% of patients in the placebo group. Patients receiving Imfinzi had estimated survival of 55.9 months compared to 33.4 months for placebo patients. The occurrence of adverse events was similar between patients receiving Imfinzi (24.4%) and placebo (24.2%). 16.4% of patients discontinued treatment due to adverse effects. Death was reported in 2.7% of patients compared to 1.9% in the placebo group.

Physician's Perspective

Lung cancer is the leading cause of cancer mortality worldwide. It is classified into two histological categories: non-small cell lung cancer or small cell lung cancer. Small cell lung cancer is further divided into limited or extensive stages, which indicate the extent to which the cancer has spread in the lungs, lymph nodes, and rest of the body. Limited-stage small cell lung cancer is an aggressive cancer with a survival rate between 15% and 30%.  Despite existing treatments, such as chemotherapy and radiation, small cell lung cancer has high relapse and mortality rates. Novel immunotherapies, like Imfinzi, are targeted to attack specific proteins found in the cancer cells. By inhibiting proteins that give cancer cells survival advantages, these drugs improve the immune system's ability to attack the cancer cells and therefore slow tumor progression.

Molecular Targets

Imfinzi is an IgG1 monoclonal antibody, an immune system protein that is programmed to bind the PD-L1 protein found in lung cancer cells. Once bound, it prevents PD-L1 from interacting with other proteins that enable the cancer cells to evade the immune system. Inhibiting these functions allows the body's immune cells, known as T cells, to kill the cancer cells. Imfinzi is classified as an immune checkpoint inhibitor because it blocks PD-L1, the checkpoint protein, from avoiding immune attack.

Company History

Imfinzi was developed by AstraZeneca, a multinational pharmaceutical and biotechnology company. AstraZeneca has manufactured other lung cancer immunotherapies, including Imjudo (tremelimumab), a monoclonal antibody against CTLA-4. Imjudo is already approved in combination with Imfinzi for certain lung and liver cancers, with ongoing trials investigating their use in other cancer subtypes. AstraZeneca researches, develops, and manufactures drugs for many diseases, including other cancers, rare disorders, and vaccines for influenza and COVID-19.

Further reading: https://www.Nejm.Org/doi/full/10.1056/NEJMoa2404873

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Microplastics May Be Leading To Lung And Colon Cancer, Study Shows

Your browser is not supporteddetroitnews.Com

detroitnews.Com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.

Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on detroitnews.Com

---